References
Hagi T, Makino T, Yamasaki M, et al. Dysphagia score as a predictor of adverse events due to triplet chemotherapy and oncological outcomes in 434 consecutive patients with esophageal cancer. Ann Surg Oncol. 2019;26(13):4754–64.
Sugawara K, Fukuda T, Kishimoto Y, et al. Impacts of pretreatment esophageal stenosis on survival of esophageal cancer patients. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12945-8
Okuno T, Wakabayashi M, Kato K, et al. Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). Int J Clin Oncol. 2017;22(6):1042–9.
Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40(4_suppl):238–238.
Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors have no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sugawara, K., Fukuda, T. ASO Author Reflections: Significance of Esophageal Cancerous Stenosis: The Nutritional, Survival, and Oncological Impacts. Ann Surg Oncol 30, 2713–2714 (2023). https://doi.org/10.1245/s10434-022-12947-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-12947-6